Nothing Special   »   [go: up one dir, main page]

RS55073B1 - Piridin-2-amidi korisni kao cb2 agonisti - Google Patents

Piridin-2-amidi korisni kao cb2 agonisti

Info

Publication number
RS55073B1
RS55073B1 RS20160666A RSP20160666A RS55073B1 RS 55073 B1 RS55073 B1 RS 55073B1 RS 20160666 A RS20160666 A RS 20160666A RS P20160666 A RSP20160666 A RS P20160666A RS 55073 B1 RS55073 B1 RS 55073B1
Authority
RS
Serbia
Prior art keywords
pyridin
agonists
amides useful
amides
useful
Prior art date
Application number
RS20160666A
Other languages
English (en)
Inventor
Caterina Bissantz
Uwe Grether
Paul Hebeisen
Atsushi Kimbara
Qingping Liu
Matthias Nettekoven
Marco Prunotto
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Christoph Ullmer
Zhiwei Wang
Wulun Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS55073B1 publication Critical patent/RS55073B1/sr
Publication of RS55073B9 publication Critical patent/RS55073B9/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
RS20160666A 2011-06-10 2012-06-07 Piridin-2-amidi korisni kao cb2 agonisti RS55073B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011075606 2011-06-10
PCT/EP2012/060785 WO2012168350A1 (en) 2011-06-10 2012-06-07 Pyridin- 2 -amides useful as cb2 agonists
EP12725834.1A EP2718266B9 (en) 2011-06-10 2012-06-07 Pyridin-2-amides useful as cb2 agonists

Publications (2)

Publication Number Publication Date
RS55073B1 true RS55073B1 (sr) 2016-12-30
RS55073B9 RS55073B9 (sr) 2019-07-31

Family

ID=46208600

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20180645A RS57262B1 (sr) 2011-06-10 2012-06-07 Piridin -2- amidi upotrebljivi kao cb2 agonisti
RS20160666A RS55073B9 (sr) 2011-06-10 2012-06-07 Piridin-2-amidi korisni kao cb2 agonisti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20180645A RS57262B1 (sr) 2011-06-10 2012-06-07 Piridin -2- amidi upotrebljivi kao cb2 agonisti

Country Status (36)

Country Link
US (2) US9321727B2 (sr)
EP (2) EP3072886B1 (sr)
JP (3) JP5997265B2 (sr)
KR (1) KR20140042848A (sr)
CN (2) CN106349156B (sr)
AR (1) AR086881A1 (sr)
AU (2) AU2012266369B2 (sr)
BR (1) BR112013031463A2 (sr)
CA (1) CA2835745A1 (sr)
CL (1) CL2013003486A1 (sr)
CO (1) CO6811864A2 (sr)
CR (1) CR20130616A (sr)
CY (1) CY1117878T1 (sr)
DK (2) DK2718266T3 (sr)
EA (2) EA027247B1 (sr)
EC (1) ECSP13013074A (sr)
ES (2) ES2588327T3 (sr)
HK (1) HK1231465A1 (sr)
HR (2) HRP20161064T2 (sr)
HU (2) HUE027669T2 (sr)
IL (2) IL229685B (sr)
LT (1) LT3072886T (sr)
MA (1) MA35245B1 (sr)
MX (1) MX339992B (sr)
MY (1) MY184978A (sr)
PE (2) PE20180037A1 (sr)
PH (1) PH12016501375A1 (sr)
PL (2) PL2718266T3 (sr)
PT (2) PT3072886T (sr)
RS (2) RS57262B1 (sr)
SG (1) SG10201604687QA (sr)
SI (2) SI2718266T1 (sr)
TR (1) TR201808273T4 (sr)
TW (1) TWI567062B (sr)
UA (1) UA114087C2 (sr)
WO (1) WO2012168350A1 (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
LT2928868T (lt) 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
SG11201504416XA (en) * 2012-12-07 2015-07-30 Hoffmann La Roche Novel pyridine derivatives
MY179412A (en) * 2012-12-07 2020-11-05 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
IN2015DN03145A (sr) 2012-12-07 2015-10-02 Hoffmann La Roche
MY176797A (en) 2013-03-07 2020-08-21 Hoffmann La Roche Novel pyrazol derivatives
CN105121436B (zh) * 2013-03-26 2018-07-27 豪夫迈·罗氏有限公司 新的吡啶衍生物
NZ712030A (en) 2013-05-02 2021-03-26 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
SI2991987T1 (en) 2013-05-02 2018-08-31 F. Hoffmann-La Roche Ag Purine Derivatives as CB2 receptor agonists
MX2016008688A (es) * 2013-12-30 2017-01-12 Lifesci Pharmaceuticals Inc Compuestos terapéuticos inhibidores.
JP6654574B2 (ja) * 2014-04-04 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド
AU2015239537B2 (en) * 2014-04-04 2019-04-04 Eidgenoessische Technische Hochschule Zuerich 5,6-disubstituted pyridine-2-carboxamides as Cannabinoid receptor agonists
CN104004006B (zh) * 2014-05-15 2016-04-06 广州康瑞泰药业有限公司 一种3,6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成方法
CN104003934B (zh) * 2014-06-13 2016-04-13 西华大学 6-氯-3-氟-2-吡啶甲酸的合成
GB201415569D0 (en) * 2014-09-03 2014-10-15 C4X Discovery Ltd Therapeutic Compounds
NZ741566A (en) 2015-10-23 2024-07-05 Navitor Pharm Inc Modulators of sestrin-gator2 interaction and uses thereof
JP2019500330A (ja) * 2015-11-26 2019-01-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリパノソーマ抑制剤
SI3386951T1 (sl) * 2015-12-09 2020-07-31 F. Hoffmann-La Roche Ag Fenilni derivati kot agonisti kanabinoidnega receptorja 2
GB201601703D0 (en) 2016-01-29 2016-03-16 C4X Discovery Ltd Therapeutic compounds
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
CN110809467B (zh) * 2017-04-26 2023-03-10 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
TW201904943A (zh) 2017-06-20 2019-02-01 瑞士商赫孚孟拉羅股份公司 新穎吡啶衍生物
PE20210368A1 (es) * 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
CN112119068A (zh) * 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
AU2019366312A1 (en) 2018-10-22 2021-05-20 Novartis Ag Crystalline forms of potassium channel modulators
MX2021004710A (es) 2018-10-24 2021-06-04 Navitor Pharm Inc Compuestos polimorficos y usos de los mismos.
CN109665982B (zh) * 2019-01-22 2022-07-08 深圳市第二人民医院 奈非西坦中间体2-吡咯烷酮的合成方法
AU2020376950A1 (en) 2019-11-01 2022-06-09 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
US20230285377A1 (en) * 2020-03-23 2023-09-14 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
JP2024524981A (ja) * 2021-06-24 2024-07-09 レザボア ニューロサイエンス，インコーポレイテッド Ｅｐ２アンタゴニスト化合物
AU2023231748A1 (en) * 2022-03-11 2024-09-05 Syngenta Crop Protection Ag Herbicidal compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005965D0 (en) 1990-03-16 1990-05-09 Shell Int Research Herbicidal carboxamide derivatives
GB9025828D0 (en) * 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
CA2069667A1 (en) * 1991-05-31 1992-12-01 Hideo Nagata Leukotriene b4 antagonist
TW226012B (sr) * 1991-11-19 1994-07-01 Dunlena Pty Ltd
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
WO2004014844A2 (en) * 2002-08-09 2004-02-19 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
US20070149547A1 (en) * 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20070244153A1 (en) * 2004-07-21 2007-10-18 Mitsui Chemicals, Inc. Diamine Derivative, Process of Preparation Thereof, and Fungicide Comprising Diamine Derivative as an Active Ingredient
DE602006007563D1 (de) 2005-04-06 2009-08-13 Hoffmann La Roche Agonisten
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
SI2041093T1 (sl) 2006-06-28 2010-07-30 Glaxo Group Ltd Derivati piperazinila, uporabni pri zdravljenju bolezni, ki jih posreduje receptor gpr38
CA2664310A1 (en) * 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
KR101114704B1 (ko) * 2006-10-04 2012-03-14 에프. 호프만-라 로슈 아게 Ｃｂ2 수용체 조절제로서 피라진-2-카복스아마이드 유도체
WO2008106692A1 (en) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
SE535157C2 (sv) * 2010-07-14 2012-05-02 Fairchild Semiconductor Konduktivitetsmodulering i en bipolär transistor i kiselkarbid
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
CR20130616A (es) 2018-01-26
CY1117878T1 (el) 2017-05-17
ES2673614T3 (es) 2018-06-25
EA201391822A1 (ru) 2014-05-30
DK2718266T3 (en) 2016-06-13
TW201311645A (zh) 2013-03-16
RS55073B9 (sr) 2019-07-31
CN103608332A (zh) 2014-02-26
IL229685A0 (en) 2014-01-30
MX2013014564A (es) 2014-03-21
CN103608332B (zh) 2016-09-28
HUE037666T2 (hu) 2018-09-28
EP3072886B1 (en) 2018-04-18
JP2014516071A (ja) 2014-07-07
CN106349156A (zh) 2017-01-25
JP2018150367A (ja) 2018-09-27
MA35245B1 (fr) 2014-07-03
CN106349156B (zh) 2018-12-11
HRP20180897T1 (hr) 2018-07-13
BR112013031463A2 (pt) 2016-12-06
MY184978A (en) 2021-04-30
SI2718266T1 (sl) 2016-08-31
SG10201604687QA (en) 2016-07-28
PE20141583A1 (es) 2014-10-25
ECSP13013074A (es) 2014-01-31
PL3072886T3 (pl) 2018-08-31
UA114087C2 (xx) 2017-04-25
PT3072886T (pt) 2018-06-12
EP3072886A1 (en) 2016-09-28
EA023287B1 (ru) 2016-05-31
TWI567062B (zh) 2017-01-21
TR201808273T4 (tr) 2018-07-23
NZ617464A (en) 2016-01-29
JP6484746B2 (ja) 2019-03-13
EA027247B1 (ru) 2017-07-31
DK3072886T3 (en) 2018-06-25
HK1231465A1 (zh) 2017-12-22
WO2012168350A1 (en) 2012-12-13
MX339992B (es) 2016-06-21
AU2017200801A1 (en) 2017-03-02
EP2718266B9 (en) 2016-11-30
SI3072886T1 (en) 2018-07-31
PH12016501375A1 (en) 2017-12-11
US9321727B2 (en) 2016-04-26
EP2718266A1 (en) 2014-04-16
CO6811864A2 (es) 2013-12-16
HRP20161064T1 (hr) 2016-10-21
LT3072886T (lt) 2018-07-10
PT2718266T (pt) 2016-07-11
AU2012266369A1 (en) 2013-11-21
US20120316147A1 (en) 2012-12-13
ES2588327T3 (es) 2016-11-02
EA201591527A1 (ru) 2016-04-29
EP2718266B1 (en) 2016-05-25
US20160137606A1 (en) 2016-05-19
IL256826B (en) 2018-08-30
AU2017200801B2 (en) 2018-11-22
AU2012266369B2 (en) 2016-11-10
ES2588327T9 (es) 2017-02-21
NZ715284A (en) 2017-06-30
HUE027669T2 (en) 2016-11-28
JP2017031162A (ja) 2017-02-09
CL2013003486A1 (es) 2014-11-03
JP6349360B2 (ja) 2018-06-27
JP5997265B2 (ja) 2016-09-28
AR086881A1 (es) 2014-01-29
PL2718266T3 (pl) 2016-11-30
KR20140042848A (ko) 2014-04-07
PE20180037A1 (es) 2018-01-09
HRP20161064T2 (hr) 2017-02-24
IL229685B (en) 2018-02-28
CA2835745A1 (en) 2012-12-13
RS57262B1 (sr) 2018-08-31

Similar Documents

Publication Publication Date Title
HRP20180897T1 (hr) Derivati piridin-2-amida korisni kao cb2-agonisti
HRP20171459T1 (hr) Piridin-2-amidi korisni kao agonisti cb2
HRP20171445T1 (hr) Piridin-2-amidi korisni kao agonisti cb2
HK1203196A1 (en) Substituted benzylpyrazoles
HK1190707A1 (zh) 作為 激動劑的 -氨基-吡啶類
GB2503849B (en) Intrinsically-calibrated tribometer
EP2663331A4 (en) NEW USES
GB201119167D0 (en) Novel bachteriophages
ZA201402298B (en) Heterocyclylpyri (mi)dinylpyrazole as fungicidals
GB201116152D0 (en) Cannabinoid-2-receptor agonists
GB201116151D0 (en) Cannabinoid-2-receptor agonists
GB201113206D0 (en) Novel uses
GB201107365D0 (en) Find my car-Carlocator
GB201109229D0 (en) New uses
GB201107854D0 (en) Novel 5-hydroxy-5-aryl-pyrrol-2-ones
GB201113923D0 (en) Novel combinations